Advocacy group to sue pharmacies over lack of translators
NEW YORK An advocacy group for immigrants will take action against pharmacies that it accuses of failing to provide translations for medications to customers who don’t speak English, the group announced Wednesday.
The action by Make the Road New York comes on the one-year anniversary of a complaint that it filed with state Attorney General Mario Cuomo. That complaint targeted 16 pharmacies, though the number has doubled since then, according to NY1 News.
The group also announced the release of a report, titled “Bad Medicine,” which would include 35 testimonies that it says show “how the lack of translated labels and interpretation services impairs access to healthcare and puts people in danger.”
Lannett’s generic antibiotic receives FDA approval
PHILADELPHIA The Food and Drug Administration has approved Lannett Company’s application for a generic version of Par Pharmaceutical’s Adoxa, Lannett announced Friday.
The drug, known generically as doxycycline tablets, will be available in doses of 75 mg and 150 mg.
Combined sales of generic doxycycline tablets in those doses were $25.8 million in 2007, according to Wolters Kluwer. The drug is an antibiotic used for urinary-tract infections, sexually transmitted infections, acne and others.
Pfizer to shift some biotech workers to California
SAN FRANCISCO Pfizer is planning on moving about 100 of its employees, including the headquarters of its new Biotherapeutics and Bioinnovation Center, to San Francisco, according to the San Francisco Business Times. The new location will be used to help develop Pfizer’s biotech pipeline.
Pfizer agreed Friday to a long-term lease of almost the entire five-story, 105,000-square-foot west wing of Alexandria Real Estate Equities planned office/laboratory complex in Mission Bay.
Pfizer will move to the complex starting in early 2010, according to a company spokeswoman. Biotech industry veteran Corey Goodman, who was hired last year when the BBC was created, will head the new BBC location.
According to Goodman, “as much as 25 percent of Pfizer’s pipeline could be in biotherapeutics, and one in five drugs on the market would be a biotherapeutic.”